{"id":"gpasit-tm","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"gpASIT+TM works by extracting a patient's T cells, genetically modifying them to recognize cancer-specific antigens, and then reinfusing them to attack and destroy cancer cells. This approach allows for a personalized and targeted treatment approach, potentially reducing side effects and improving efficacy.","oneSentence":"gpASIT+TM is a personalized immunotherapy that uses a patient's own immune cells to target and destroy cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:17.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT03724240","phase":"PHASE3","title":"Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis","status":"UNKNOWN","sponsor":"ASIT Biotech S.A.","startDate":"2019-01-02","conditions":"Hay Fever","enrollment":624},{"nctId":"NCT02560948","phase":"PHASE3","title":"Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2015-12","conditions":"Hay Fever","enrollment":554},{"nctId":"NCT02156791","phase":"PHASE2","title":"Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2013-08","conditions":"Hay Fever","enrollment":61},{"nctId":"NCT01308021","phase":"PHASE2","title":"Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2010-12","conditions":"Grass Pollen Allergy, Hay Fever","enrollment":202},{"nctId":"NCT00813046","phase":"PHASE1","title":"Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2008-12","conditions":"Seasonal Allergic Rhinoconjunctivitis","enrollment":8},{"nctId":"NCT01506375","phase":"PHASE2","title":"Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2011-11","conditions":"Hay Fever","enrollment":24},{"nctId":"NCT00833066","phase":"PHASE1, PHASE2","title":"Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2009-02","conditions":"Seasonal Allergic Rhinoconjunctivitis","enrollment":54},{"nctId":"NCT01111279","phase":"PHASE1","title":"Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2010-03","conditions":"Seasonal Allergic Rhinoconjunctivitis","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"gpASIT+TM","genericName":"gpASIT+TM","companyName":"BioTech Tools S.A.","companyId":"biotech-tools-s-a","modality":"Biologic","firstApprovalDate":"","aiSummary":"gpASIT+TM is a personalized immunotherapy that uses a patient's own immune cells to target and destroy cancer cells. Used for Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}